Impact of ART Adherence on HIV Persistence and Inflammation
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Human Immunodeficiency Virus
- Sponsor
- University of Colorado, Denver
- Enrollment
- 71
- Locations
- 1
- Primary Endpoint
- Level of tenofovir diphosphate in dried blood spots associated with the size of the HIV reservoir measured by the amount of CA-RNA and CA-DNA in PBMCs.
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the relationship between anti-retroviral therapy (ART) adherence with levels of human immunodeficiency virus (HIV) reservoir and residual viremia in suppressed, HIV-infected individuals on chronic ART.
Detailed Description
Understanding whether the size and dynamics of the HIV reservoir are associated with adherence, measured by an objective biomarker, could have significant clinical and therapeutic implications for ART and HIV cure. 1. First, this aim will quantify levels of CA-RNA, CA-DNA, and plasma residual viremia in suppressed, HIV infected individuals and correlate them with levels of TFV-DP in DBS as a measure of cumulate drug exposure (adherence). 2. Second, this study will evaluate the changes in the HIV reservoir in relation to changes in ART adherence over time.
Investigators
Eligibility Criteria
Inclusion Criteria
- •HIV-infected males and females,
- •Ages 18 years and older,
- •Taking any TFV-based regimen,
- •HIV suppression \<20 copies/ml for at least 12 months;
- •Not co-infected with HCV;
- •Able and willing to give informed consent.
Exclusion Criteria
- •Refusal to participate.
Outcomes
Primary Outcomes
Level of tenofovir diphosphate in dried blood spots associated with the size of the HIV reservoir measured by the amount of CA-RNA and CA-DNA in PBMCs.
Time Frame: 6 months
Evaluation of variations in ART cumulative adherence are associated with the size of the HIV reservoir and with the degree of chronic inflammation and immune activation in HIV-infected, virologically suppressed individuals.
Secondary Outcomes
- Level of self-reported adherence (4-day, 30-day and 3-months using a visual analog scale) associated with the size of the HIV reservoir measured by CA-RNA and CA-DNA in PBMCs.(6 months)